During the past decades, prostate cancer (PCa), with an annual incident rate much higher than any other cancer, is the most commonly diagnosed cancer in American men. PCa has a relatively low progression rate yet the survival percentage decreases dramatically once the cancer has metastasized. Identifying aggressive from indolent PCa to prevent metastasis and death is critical to improve outcomes for patients with PCa. Standard procedure for assessing the aggressiveness of PCa involves the removal of tumor tissues by transrectal (TR) ultrasound (US) guided needle biopsy. The microscopic architecture of the biopsied tissue is visualized by histological or immunohistochemical staining procedures. The heterogeneity of the microscopic architecture is characterized by a Gleason score, a quantitative description of the aggressiveness of PCa. Due to the inability to identify the cancer cells, most noninvasive imaging modalities can only provide diagnosis of PCa at limited accuracy. This study investigates the feasibility of identifying PCa tumors and characterizing the aggressiveness of PCa by photoacoustic imaging assisted by cancer targeting polyacrylamide (PAA) nanoparticles (NPs). PAA is a biocompatible material used in clinics for the past 20 years. PAA NPs can protect capsulated optical contrast agents from interference by enzymes and enable prolonged systematic circulation in the living biological environment. The cancer targeting mechanism is achieved by conjugating the NPs to F3 peptides, which trace nucleolin overexpressed on the surface of cancer cells. Preliminary studies have shown that the NPs are capable of staining the PCa cells in vivo.
INTRODUCTION
During the past decades, Prostate cancer (PCa), with an annual incidence rate much higher than any other cancer, is the most commonly diagnosed cancer in American men [1] . PCa is ranked only next to lung and bronchus cancer in all cancer related deaths. PCa has a relatively low progression rate. Patients with early diagnosed PCa have a five year survival rate close to 100% yet the percentage decreases dramatically once the cancer has metastasized. Identifying the high grade cancer in prostate and precise therapy in prevention of metastasis is of particular benefit for PCa patients.
Blood test for the biomarkers is the primary screening approaches for PCa [2] . With preliminary diagnosis of PCa by blood test, the patients will be recommended for digital rectal examination, transrectal ultrasonography, and eventually the Ultrasound (US) guided biopsy, the gold standard procedure for evaluating the presence of PCa. The microscopic architectures of the biopsied tissues, stained and visualized by histology procedures, are observed by pathologists and assigned a Gleason grade [3] , a highly prognostic factor for prostate cancer, as the conclusion for the diagnosis procedure.
However, US imaging, with low sensitivity to PCa, could either miss cancer or lead to the undersampling of aggressive cancer. Non-guided and saturating biopsies following a predetermined pattern overlaid onto the prostate contour delineated by US are thereby frequently employed. More than 20 biopsy cores, each with a diameter of approximately 1mm and length of 15 mm, could be extracted [4] . Such procedure could cause anxiety, pain, potentially unrecoverable damage to the neurovascular bundle and consequently erectile dysfunction [5] . A strong need thereby exists for minimal invasive and cost-efficient technique that can 1) identify the malignancies in prostate to guide biopsy and/or 2) evaluate the aggressiveness of the malignancies without removing the tissue.
The recent development of hydrogel nanoparticle (NP) technology has allowed the targeted delivery of functional agents to the cancer cells by recognizing the specific proteins on the cancer cell surfaces [6] . A unique advantage of the polymer based hydrogel NPs is that their biocompatibility and chemically inertness assure a long circulation life and thereby minimize the toxicity of the functional loadings. Such NPs, when loaded with imaging contrast enhancement materials, facilitate in vivo tumor staining for the direct observation by noninvasive imaging modalities [7] [8] [9] [10] . The NPs could also precisely deliver therapeutic drugs to the malignant tissues, enabling localized cancer treatment. In our previous studies, we have successfully developed cancer-targeting [6] and specifically prostate cancer targeting NPs [9] for tumor staining. Yet the major diagnostic challenge of prostate cancer, besides the delineation of the tumors, is the grading of the cancers by their microscopic architectures.
Laser (photo-) induced ultrasound (-acoustic) imaging, namely photoacoustic (PA) imaging (PAI), is a novel imaging modality combining the advantages of both optical and ultrasound imaging [11, 12] . A PAI system can be achieved by integrating a laser system to a clinical ultrasound system. PAI thereby possesses the intrinsic advantage in prostate imaging, over any other imaging modality, in that it is naturally coregistered with transrectal US for improved guidance for biopsy. Due to its multi-physics and multi-scale nature, PAI combines the excellent optical sensitivity for observing macroscopic, chemical contents and US resolution for observing the microscopic, physical architectures in biological tissue.
This study investigated the capability of F3 peptide conjugated NP for the characterization architectures in PCa tumors.
APPROACHES

In vitro test of the F3 peptide conjugated NPs with human PCa cells.
The nanoparticles were incubated with human PCa cells (DU145) for 2 hours. NPs were labeled with FITC (green), while the cell nucleus was stained with DAPI (blue). NP concentration: 1.0 mg/mL; scale bar: 25 µm. These results demonstrated that the attachment of F3 peptide improved the uptake of PEG-PAA NPs into both DU145 cells significantly, which is related with the overexpression of nucleolin on the surface of both kinds of tumor cells. Dose (mg / kg body weight)
In vivo test with xenograft tumor in rats
The NPs were tested with DU145 xenograft tumors in rats. Subcutaneous xenograft tumors were generated in nude rats (100-150 g). Approximately 5-10 million human derived tumor cells (DU145) in 0.2-0.5 ml of cultured media was implanted under manual restraint. Animals were physically monitored twice a week for tumor growth. Large tumors of around 1 cm 3 were formed at the inoculation site by 7-14 days post-inoculation. When the tumors had grown to the expected volume, the rats were injected through tail vein with F3 conjugated PEG-PAA NPs loaded with Coomassie Blue CB at 60, 120 and 250 mg/Kg of body weight. The animals were anesthetized and PAI was performed in the experiment setup in Fig. 2 . Fig. 2 Experiment setup for xenograft tumor imaging in vivo. 590 nm laser targeting the optical absorption peak of Coomassie Blue encapsulated in the NPs were used. The laser was delivered through a fiber optics bundle. A US probe acquires US and PA measurements, which is processed and displayed by the Verasonics US platform [10] .
Representative images of the tumors were shown in Fig. 3(a) . The dynamics of the tumor in rats are shown Fig. 3(b)(c) . Significant optical contrast enhancement can be observed. In vivo staining the architecture in prostate using the F3 conjugated nanoparticles 
DISCUSSION AND CONCLUSION
This study validated the F3 conjugated hydrogel NPs can enhance the optical contrast of PCa tumors and visualize the tissue architectures inside the tumors.
F3 peptide targets general cancer cells. Conjugating nanoparticles with antibodies of specific proteins expressed by metastatic PCa cells could further enrich the diagnostic information. The encapsulated optical contrast enhancing agents can also be replaced with those possessing strong optical absorption in the 700-900 nm range to further increase the achievable imaging depth.
